Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G W Boyd

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Clinical and Experimental Pharmacology & Physiology|May 1, 1983
Prevention of structural arteriolar changes in DOCA hypertension with hydrallazineJ H Vial, A C Yong, G W Boyd
American Heart Journal|January 1, 1972
Renal hypertension and angiotensin antibodiesG J Macdonald, G W Boyd, W S Peart
The Journal of Pharmacy and Pharmacology|April 1, 1980
The availability of nitroglycerin from parenteral solutionsM S Roberts, P A Cossum, A J Galbraith, et al.
Lancet (London, England)|August 12, 1978
Loss of nitroglycerin from intravenous infusion setsP A Cossum, A J Galbraith, M S Roberts, et al.
Journal of Hypertension|February 1, 1989
Structural changes vary along individual arterioles in deoxycorticosterone acetate hypertensive ratsJ H Vial, A C Yong, M B Walker, et al.
Clinical Science|January 1, 1972
The role of angiotensin II in the control of aldosterone in manG W Boyd, A R Adamson, M Arnold, et al.
Lancet (London, England)|February 14, 1970
Renal-clip hypertension in rabbits immunised against angiotensin IIW J Louis, G J Macdonald, V Renzini, et al.
European Journal of Pharmacology|April 1, 1993
The metabolism and activation of 15,16-dihydrocyclopenta[a]phenanthren-17-one by cytochrome P-450 proteinsG W Boyd, R J Young, R G Harvey, et al.
Carcinogenesis|August 1, 1993
The in vitro metabolic activation of the 11-trifluoromethyl analogue of the potent carcinogen 15,16-dihydro-11-methyl-cyclopenta[a]-phenanthren-17-one to mutagensG W Boyd, H H Zepik, L M King, et al.
Circulation Research|August 1, 1970
Renal-clip hypertension in rabbits immunized against angiotensin IIG J Macdonald, W J Louis, V Renzini, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Clinical and Experimental Pharmacology & Physiology|May 1, 1983
Prevention of structural arteriolar changes in DOCA hypertension with hydrallazineJ H Vial, A C Yong, G W Boyd
American Heart Journal|January 1, 1972
Renal hypertension and angiotensin antibodiesG J Macdonald, G W Boyd, W S Peart
The Journal of Pharmacy and Pharmacology|April 1, 1980
The availability of nitroglycerin from parenteral solutionsM S Roberts, P A Cossum, A J Galbraith, et al.
Lancet (London, England)|August 12, 1978
Loss of nitroglycerin from intravenous infusion setsP A Cossum, A J Galbraith, M S Roberts, et al.
Journal of Hypertension|February 1, 1989
Structural changes vary along individual arterioles in deoxycorticosterone acetate hypertensive ratsJ H Vial, A C Yong, M B Walker, et al.
Clinical Science|January 1, 1972
The role of angiotensin II in the control of aldosterone in manG W Boyd, A R Adamson, M Arnold, et al.
Lancet (London, England)|February 14, 1970
Renal-clip hypertension in rabbits immunised against angiotensin IIW J Louis, G J Macdonald, V Renzini, et al.
European Journal of Pharmacology|April 1, 1993
The metabolism and activation of 15,16-dihydrocyclopenta[a]phenanthren-17-one by cytochrome P-450 proteinsG W Boyd, R J Young, R G Harvey, et al.
Carcinogenesis|August 1, 1993
The in vitro metabolic activation of the 11-trifluoromethyl analogue of the potent carcinogen 15,16-dihydro-11-methyl-cyclopenta[a]-phenanthren-17-one to mutagensG W Boyd, H H Zepik, L M King, et al.
Circulation Research|August 1, 1970
Renal-clip hypertension in rabbits immunized against angiotensin IIG J Macdonald, W J Louis, V Renzini, et al.
Pageof 6